Skip to search formSkip to main contentSkip to account menu

erlotinib

Known as: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular… 
National Institutes of Health

Related topics

Related topics

8 relations

Narrower (4)

CP 358774Erlotinib HydrochlorideOSI-774Tarceva
HER1 Antagonists [MoA]NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibitionerlotinib 100 MG Oral Tablet [Tarceva]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Purpose: Tumors from 50% of epidermal growth factor receptor (EGFR) mutant non–small cell lung cancer patients that develop… 
Highly Cited
2008
Highly Cited
2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
PURPOSE We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma… 
Highly Cited
2007
Highly Cited
2007
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
Purpose: Data from two large phase III studies were analyzed to characterize the correlation between the occurrence of rash… 
Highly Cited
2007
Highly Cited
2007
Erlotinib in Previously Treated Non-Small-Cell Lung Cancer
Highly Cited
2006
Highly Cited
2006
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non–small cell lung… 
Highly Cited
2006
Highly Cited
2006
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion… 
Highly Cited
2006
Highly Cited
2006
METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS
Metabolism and excretion of erlotinib, an orally active inhibitor of epidermal growth factor receptor tyrosine kinase, were… 
Highly Cited
2006
Highly Cited
2006
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
PURPOSE This report describes the quality of life (QOL) findings of a randomized placebo controlled study of erlotinib, an… 
Highly Cited
2005
Highly Cited
2005
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR… 
Review
2003
Review
2003
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)